Business Wire

Europe Sees AI-Driven Cloud Growth in Q4 as Managed Services Demand Slows: ISG Index™

Share

Combined market ACV up 17% from prior year, but down 7% from Q3Managed services ACV off 5%, while XaaS soars 42%

AI-driven demand for cloud services fueled overall growth in Europe’s IT and business services market in the fourth quarter, even as demand for managed services slowed, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.

The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows ACV for the combined market (both managed services and cloud-based as-a-service) advanced 17 percent, to US $8.3 billion, in the fourth quarter, but slowed by 7 percent sequentially from a record third quarter.

“Europe came off a record high demand for managed services in the third quarter, as continued economic uncertainty and geopolitical tensions weighed on the market during the fourth quarter,” said Steve Hall, president, ISG EMEA. “On the plus side, demand for cloud services surged to an all-time quarterly high, as enterprises reaccelerated their move to the cloud, seeking overall cost savings and greater efficiency and innovation through AI.”

Q4 Results by Segment

Managed services ACV for the fourth quarter declined 5 percent year on year, to US $3.7 billion, and was down 25 percent sequentially from a record third quarter. There were 283 managed services contracts awarded in the quarter, up 10 percent versus the prior year, but down 8 percent quarter on quarter. During the fourth quarter, only one mega-deal (contract with an annual value of $100 million or more) was awarded, down sharply from the six mega deals awarded in Q3. At the other end of the spectrum, deals in the US $5 million to US $9 million category, the smallest measured by the ISG Index, rose 12 percent versus the prior year.

Within managed services, IT outsourcing (ITO) slumped 7 percent year on year, to US $2.7 billion, driven lower by an 18 percent decline in application and development services, the largest ITO segment. Business process outsourcing (BPO), meanwhile, rose 2 percent, to US $992 million, boosted by facilities management and HR services.

ACV in the cloud-based as-a-service (XaaS) segment soared 42 percent versus the prior year, to US $4.6 billion, and was up 14 percent against the prior quarter. The market’s percentage growth year on year was the most in a quarter since the second quarter of 2022. Over the last four quarters, Europe’s demand for cloud services has grown an average of 23.5 percent a quarter.

Both the infrastructure-as-a-service (IaaS) and software-as-a-service (SaaS) segments turned in strong performances in Q4. IaaS climbed 52 percent year on year, to US $3.4 billion, while SaaS rose 21 percent, to $1.2 billion.

Full-Year Results

Combined market ACV was up 14 percent for the full year, to a record US $32.6 billion, surpassing the previous annual record in 2022 by 8 percent. In 2023, the combined market was down 5 percent.

Managed services had a record year, with ACV of US $16.6 billion, up 5.6 percent, although the entire upside for the year was driven by strong growth in Q3. ITO, at US $12.4 billion, was up 6 percent, while BPO, at US $4.1 billion, was up 4 percent. A total of 1,164 managed services contracts were awarded in 2024, up 11 percent from the prior year. Thirteen of those were mega deals, up from 12 in the prior year, even as the combined annual value of the mega deals was down 12 percent.

New scope ACV advanced 10 percent, to a record $10.7 billion. By industry, travel and transportation ACV soared 84 percent versus the prior year, on the strength of large awards in Germany. Energy, retail and manufacturing were each up slightly, while the region’s largest sourcing sector, banking, financial services and insurance (BFSI), slumped 22 percent.

The XaaS market generated ACV of US $16.0 billion, up 23 percent, surpassing its previous annual high in 2022 by 9 percent, after slumping 11.5 percent in 2023. IaaS jumped 30 percent, to US $11.6 billion, while SaaS rose 8 percent, to US $4.4 billion. XaaS accounted for 49 percent of the combined market in 2024, up from 45 percent in 2023.

Geographic Performance

In the fourth quarter, the region’s largest market, the U.K., declined 33 percent from the prior year, to US $935 million of managed services ACV, its weakest quarter in two years after producing seven straight quarters with ACV of more than US $1 billion. Meanwhile, DACH, the region’s second-largest market, saw its ACV rise by 4 percent, to US $719 million, while number-three market France declined 11.5 percent, to US $708 million.

For the full year, the U.K. generated US $4.4 billion of managed services ACV, off 23 percent. DACH came in at $4.3 billion, up 64 percent, buoyed by several large contracts. The Nordics advanced 12 percent, to US $1.6 billion, and the Benelux market finished up 16 percent, to US $1.4 billion. France, meanwhile, was off 5 percent, to US $2.1 billion.

2025 Global Forecast

For the full year, ISG is forecasting 4.5 percent revenue growth for managed services, up from 1.8 percent growth in 2024, and 18 percent revenue growth for XaaS, in line with the prior year.

“We expect a gradual recovery in enterprise demand for IT and business services,” Hall said. “Companies are still cautious amid continuing economic and geopolitical uncertainty. In Europe, we are likely to see subdued growth, with the upcoming elections in Germany creating uncertainty in the market until the second half.

“At the same time, we see some tailwinds at play that should boost the global market,” Hall said. “AI spending continues to gain momentum, with hundreds of billions being spent on infrastructure, setting the stage for widespread adoption. In managed services, we're seeing early signs of improvement in the BFSI sector as discretionary spending begins to pick up.”

About the ISG Index™

The ISG Index™ is recognized as the authoritative source for marketplace intelligence on the global technology and business services industry. For 89 consecutive quarters, it has detailed the latest industry data and trends for financial analysts, enterprise buyers, software and service providers, law firms, universities and the media.

The 4Q24 Global ISG Index results were presented during a webcast January 16. To view a replay of the webcast and download presentation slides, visit this webpage.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including AI, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250120758250/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye